- Home
- CELC vs HCM Comparison
CELC vs HCM Comparison
Compare CELC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | HCM |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CELC | HCM |
|---|---|---|
| Price | $110.32 | $15.35 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $100.13 | $13.75 |
| AVG Volume (30 Days) | ★ 629.3K | 55.7K |
| Earning Date | 11-12-2025 | 08-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.54 |
| P/E Ratio | ★ N/A | $5.62 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.58 | $11.51 |
| 52 Week High | $116.44 | $19.50 |
Technical Indicators
Market Signals| Indicator | CELC | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 59.33 |
| Support Level | $103.00 | $14.63 |
| Resistance Level | $112.69 | $16.33 |
| Average True Range (ATR) | 6.44 | 0.43 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 70.07 | 67.09 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.